SDSaeed Daneshmandi

Saeed Daneshmandi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saeed Daneshmandi has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The suppressive function of ILC2 cells is regulated by β2-adrenergic receptor signaling in breast cancer

    by Jee Eun Choi, Qi Yan, Jianmin Wang, Nicholas J. Salgia, Jason B. Muhitch, Cameron R. MacDonald, Nathan T. Roberts, Caitlin M. James, Philip L. McCarthy, Hemn Mohammadpour, et al.

    Type II innate lymphoid cells (ILC2s) have been implicated in both tumor-promoting and tumor-suppressive functions, but the mechanism(s) underlying this functional heterogeneity is not clear. Here, we tested the hypothesis that signaling through β2-adrenergic receptor (β2-AR) drives the pro-tumor functions of ILC2s within the tumor microenvironment. Using global (β2AR−/−) and ILC2-specific conditional knockout (IL5Creβ2ARfl/fl) mouse models, we examined how β2-AR deficiency affects ILC2 function in breast cancer. We studied the impact of β2-AR function on ILC2 phenotype, gene profile, anti-tumor T cell response and breast tumor growth. β2AR inhibition resulted in an enrichment of KLRG1⁺ ILC2s with elevated GATA3 and ST2 expression in breast tumor. Loss of β2-AR signaling in ILC2s reduced their pro-tumorigenic activity and resulted in suppressed tumor growth. Additionally, β2-AR inhibition in ILC2s was associated with increased CD4⁺ T cell infiltration in breast tumors and a greater TNF-α+ CD8+ T cell response. β2-AR deficiency reprograms ILC2s toward a more immunostimulatory phenotype, promoting T cell-mediated anti-tumor immunity. These findings identify activity of the β2-AR as a key regulator of ILC2 plasticity and suggest β2-AR blockade as a promising strategy to enhance cancer immunotherapy.


  • Open Access

    6-Phosphogluconate dehydrogenase promotes mitochondrial fusion and immune suppression in tumor-associated monocytic suppressor cells

    by Saeed Daneshmandi, Qi Yan, Eduardo Cortes Gomez, Jee Eun Choi, Eriko Katsuta, Ehsan Gharib, Prashant K. Singh, Richard M. Higashi, Andrew N. Lane, Teresa W-M. Fan, et al.

    The mechanisms underlying the metabolic adaptation of myeloid cells within the tumor microenvironment remain incompletely understood. Here, we identify 6-phosphogluconate dehydrogenase (6PGD), a rate-limiting enzyme in the pentose phosphate pathway (PPP), as an important regulator of monocytic-myeloid derived suppressor cell (M-MDSC) function. Our findings reveal that tumor M-MDSCs upregulate 6PGD expression via IL-6/STAT3 signaling. Blocking 6PGD, using either genetic or pharmacological approaches, impairs the immunosuppressive function of M-MDSCs and suppresses tumor growth. Mechanistically, 6PGD inhibition leads to the accumulation of its substrate, 6-phosphogluconate (6PG), within M-MDSCs, activates the JNK1-IRS1 and PI3K-AKT-pDRP1 signaling pathways, leading to mitochondrial fragmentation and elevated mitochondrial reactive oxygen species (ROS). This metabolic shift drives M-MDSCs toward an M1-like proinflammatory phenotype. Furthermore, 6PGD blockade synergizes with anti-PD-1 immunotherapy in a preclinical tumor model, substantially improving therapeutic outcomes. Our data reveals 6PGD as a possible therapeutic target to disrupt M-MDSC function and improve cancer immunotherapy outcomes.


  • Open Access

    Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

    by Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, JeeEun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund, et al.

    Understanding the roles of myeloid cells in the tumor microenvironment (TME) has emerged as a promising strategy to identify novel targets to counteract the immunosuppressive barriers protecting multiple myeloma (MM). Neutrophils are a new cancer research focus due to their potential to reduce the efficacy of immune-based therapies. This study aimed to deepen understanding of neutrophil function in MM by analyzing freshly isolated myeloid cells from paired focal lesions (FLs) and bone marrow using single-cell RNA sequencing, immunofluorescence imaging, and functional assays. We describe 3 distinct CXCR2+ mature neutrophil subsets: TREM1+CD10+, RETN+LCN2+, and TNFAIP3+CXCL8+, each exhibiting unique phenotypes within the TME. Notably, the TREM1+CD10+ subset was highly prevalent, particularly in FLs, demonstrating potent immunosuppressive effects on T cells. This subset’s gene signature was correlated with shorter overall survival (OS) in a large data set of patients with MM, underscoring its clinical significance. Targeted inhibition of neutrophil activity through CXCR2 blockade, alone or combined with standard anti-MM therapies, significantly reduced tumor burden, improving OS in preclinical MM models. These insights into neutrophil-mediated immunosuppression in MM provide valuable knowledge regarding mechanisms driving immune evasion, and reveal new therapeutic approaches to enhance the efficacy of MM treatment.


  • Open Access

    Targeting the pentose phosphate pathway mitigates graft-versus-host disease by rewiring alloreactive T cell metabolism

    by Saeed Daneshmandi, Eun Ko, Qi Yan, Jee Eun Choi, Prashant K. Singh, Richard M. Higashi, Andrew N. Lane, Teresa W.M. Fan, Jingxin Qiu, Sophia Hani, et al.

    Glycolysis fuels cytotoxic allogeneic T cells in acute graft-versus-host disease (aGvHD), but the downstream role of glucose metabolism in modulating aGvHD remains unclear. Targeting glycolysis or glucose receptors is toxic. Therefore, we explored alternative glucose-dependent pathways, focusing on the pentose phosphate pathway (PPP). Single-cell RNA sequencing revealed PPP upregulation in allogeneic T cells during allogeneic hematopoietic cell transplantation (allo-HCT). We showed that donor T cell deficiency in 6-phosphogluconate dehydrogenase (6PGD), the second rate-limiting enzyme in the PPP, significantly reduced aGvHD severity and mortality in murine models. Functional assays demonstrated that PPP blockade led to proliferation arrest without inducing apoptosis. PPP blockade shifted T cell metabolism away from T cell dependency on glycolysis for rapid T cell proliferation. Pharmacological inhibition of the PPP through 6PGD blockade with 6-aminonicotinamide (6AN) effectively reduced aGvHD severity, like donor 6PGD-deficient T cells in an allogeneic aGvHD model. Similarly, 6AN reduced xenogeneic GvHD lethality. 6PGD inhibition preserved the graft-versus-tumor (GvT) effect, with the generation of a small subset of granzyme B hi effector T cells with potent antitumor activity. These findings highlight the PPP as a key regulator of allogeneic T cell proliferation and differentiation and identify 6PGD as a promising therapeutic target to mitigate aGvHD severity while preserving beneficial GvT effects.


  • Open Access

    Abstract 2537: Beta-glucan reprograms immunomodulatory metabolism in human macrophage and ex vivo in lung cancer tissues

    by Teresa W. M. Fan, Saeed Daneshmandi, Teresa A. Cassel, Mohammad B. Uddin, James Sledziona, Patrick T. Thompson, Penghui Lin, Richard M. Higashi, Andrew N. Lane

    We combined multiplex Stable Isotope-Resolved Metabolomics (mSIRM) with Reverse Phase Protein Array (RPPA) to map the time course changes of IM metabolic network and key protein regulators in four human donors’ MΦ’s in response to differential polarization and whole glucan particulates (WGP) treatments. We found consistent and plastic network responses to polarization durations and WGP treatments compared to those of the mouse counterparts. Consistent responses included enhanced 15N2-tryptophan catabolism to quinolinate, 2H2-glucose oxidation to ribose/ribulose-5-phosphate, and conversion of 13C5-glutamine to itaconate in response to pro-inflammatory (M1) versus anti-inflammatory (M2) stimuli. WGP robustly induced the buildup of 2H2-glucose-derived 6-phosphogluconate, -lactate, and -IMP, 13C5-glutamine-derived fructose-1,6-bisphosphate, and increased enrichment of 2H-labeled UDP-N-acetylglucosamine in M2-MΦ’s. However, the Krebs cycle activity was variably enhanced by M2 stimuli or WGP treatment. The consistent effects were related to increased release of proinflammatory IM effectors IL-1β/CXCL10/IFNγ/TNFα by M1-MΦ’s and enhanced release of IL-1β/TNFα to above M1-MΦ’s levels in WGP-treated M2-MΦ’s while boosting the latter in anti-inflammatory IL-10 release and maintenance of NAD+ synthesis. They were also related to lower phagocytosis in M1-MΦ’s and WGP-treated M2-MΦ’s versus M2-MΦ’s. Together with the expression changes of key protein regulators, we suggest enhanced tryptophan catabolism with blocked NAD+ and UTP synthesis to be key to the consistent changes in immune functions in response to M1 stimuli. Likewise, increased glucose utilization via glycolysis and the oxidative branch of the pentose phosphate pathway, and blockade of glutamine-fueled N-linked glycosylation could be linked to reversion of M2 to M1-type immune functions. Reprogrammed Krebs cycle and glutamine conversion to UTP occurred variably in WGP-treated ex vivo organotypic tissue cultures (OTCs) of human non-small cell lung cancer (NSCLC), which could reflect variable M1 repolarization of tumor associated MΦ’s. This in turn correlated with IL-1β/TNFα releases and compromised tumor status, making patient-derived OTCs a unique model for studying variable immunotherapeutic efficacy in cancer patients. In conclusion, consistent and variable IM metabolic responses were evident in four human donors’ MΦ’s. WGP repolarized some M2 to M1-type responses while boosting other M2-type responses. NSCLC OTCs from six patients showed variable M1 repolarization in response to WGP. Citation Format: Teresa W. M. Fan, Saeed Daneshmandi, Teresa A. Cassel, Mohammad B. Uddin, James Sledziona, Patrick T. Thompson, Penghui Lin, Richard M. Higashi, Andrew N. Lane. Beta-glucan reprograms immunomodulatory metabolism in human macrophage and ex vivo in lung cancer tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2537.

  • Open Access

    6-Phosphogluconate dehydrogenase (6PGD), a key checkpoint in reprogramming of regulatory T cells metabolism and function

    by Saeed Daneshmandi, Teresa Cassel, Richard M Higashi, Teresa W-M Fan, Pankaj Seth

    Cellular metabolism has key roles in T cells differentiation and function. CD4+ T helper-1 (Th1), Th2, and Th17 subsets are highly glycolytic while regulatory T cells (Tregs) use glucose during expansion but rely on fatty acid oxidation for function. Upon uptake, glucose can enter pentose phosphate pathway (PPP) or be used in glycolysis. Here, we showed that blocking 6-phosphogluconate dehydrogenase (6PGD) in the oxidative PPP resulted in substantial reduction of Tregs suppressive function and shifts toward Th1, Th2, and Th17 phenotypes which led to the development of fetal inflammatory disorder in mice model. These in turn improved anti-tumor responses and worsened the outcomes of colitis model. Metabolically, 6PGD blocked Tregs showed improved glycolysis and enhanced non-oxidative PPP to support nucleotide biosynthesis. These results uncover critical role of 6PGD in modulating Tregs plasticity and function, which qualifies it as a novel metabolic checkpoint for immunotherapy applications.


  • Open Access

    Long-term tolerance of islet allografts in nonhuman primates induced by apoptotic donor leukocytes

    by Amar Singh, Sabarinathan Ramachandran, Melanie L. Graham, Saeed Daneshmandi, David Heller, Wilma Lucia Suarez-Pinzon, Appakalai N. Balamurugan, Jeffrey D. Ansite, Joshua J. Wilhelm, Amy Yang, et al.

    Immune tolerance to allografts has been pursued for decades as an important goal in transplantation. Administration of apoptotic donor splenocytes effectively induces antigen-specific tolerance to allografts in murine studies. Here we show that two peritransplant infusions of apoptotic donor leukocytes under short-term immunotherapy with antagonistic anti-CD40 antibody 2C10R4, rapamycin, soluble tumor necrosis factor receptor and anti-interleukin 6 receptor antibody induce long-term (≥1 year) tolerance to islet allografts in 5 of 5 nonsensitized, MHC class I-disparate, and one MHC class II DRB allele-matched rhesus macaques. Tolerance in our preclinical model is associated with a regulatory network, involving antigen-specific Tr1 cells exhibiting a distinct transcriptome and indirect specificity for matched MHC class II and mismatched class I peptides. Apoptotic donor leukocyte infusions warrant continued investigation as a cellular, nonchimeric and translatable method for inducing antigen-specific tolerance in transplantation.


  • Open Access

    Barberry's ( Berberis integerrima ) ingredients suppress T-cell response and shift immune responses toward Th2: an in vitro study

    by Shirin Fateh, Shaghayegh Pishkhan Dibazar, Saeed Daneshmandi

    Food and medicinal applications of barberry date back to 2500 years ago. This study investigates Berberis integerrima impact on lymphocytic immune responses. Balb/c splenocytes were treated by 0.001-1000 μg/ml of B. integerrimaaqueous and alcoholic extracts in presence of phytohemagglutinin and lipopolysaccharide mitogens. Cell proliferation was assayed and cytokines were measured using ELISA. Both extracts suppressed proliferation of phytohemagglutinin stimulated splenocytes (as T cells), while alcoholic extract induced expansion of lipopolysaccharide activated cells (as B lymphocytes) and unstimulated cells (p < 0.05). Both barberry extracts suppressed IFN-γ production (p < 0.05) and enhanced IL-4, IL-10 and TGF-β release from splenocytes (p < 0.05). Both extracts could suppress T-cell and enhance B-cell proliferation and shift immune responses toward Th2.


    • 1 February 2015
      • Vol. 14  (1) , 48-54

    Lack of Association between Toll Like Receptor-2 and Toll Like Receptor-4 Gene Polymorphisms and Other Feature in Iranian Asthmatics Patients.

    by Hamid Bahrami, Saeed Daneshmandi, Hasan Heidarnazhad, Ali Akbar Pourfathollah

    Asthma as a chronic inflammatory airway disease is considered to be the most common chronic disease that is involving genetic and environmental factors. Toll like receptors (TLRs) and other inflammatory mediators are important in modulation of inflammation. In this study, we evaluated the role of TLR2 Arg753Gln and TLR4 Asp299Gly polymorphisms in the asthma susceptibility, progress, control levels and lung functions in Iranian patients. On 99 asthmatic patients and 120 normal subjects, TLR2 Arg753Gln and TLR4 Asp299Gly polymorphisms were evaluated by PCR-RFLP method recruiting Msp1 and Nco1 restriction enzymes, respectively. IgE serum levels by ELISA technique were determined and asthma diagnosis, treatment and control levels were considered using standard schemes and criteria. Our results indicated that the genotype and allele frequencies of the TLR2 Arg753Gln and TLR4 Asp299Gly polymorphisms were not significantly different between control subjects and asthmatics and were not related to in asthma features such as IgE levels, asthma history and pulmonary factors. Wherease some previous studies indicated TLRs and their polymorphisms might have some role in asthma incidence and features, our data demonstrated that TLR2 Arg753Gln and TLR4 Asp299Gly gene variants were not risk factors for asthma or its features in Iranian patients. Genetic complexity, ethnicity, influence of other genes or polymorphisms may overcome these polymorphisms in our asthmatics.


  • Open Access

    Clove (Syzygium aromaticum) ingredients affect lymphocyte subtypes expansion and cytokine profile responses: An in vitro evaluation

    by Shaghayegh Pishkhan Dibazar, Shirin Fateh, Saeed Daneshmandi

    Clove (Syzygium aromaticum) has been used in folk medicine in many disorders. The present work aimed to investigate effects of clove essential oil as eugenol and water soluble ingredients on mouse splenocytes. Clove extracts were harvested and in different concentrations (0.001-1000 μg/mL) were affected to splenocytes and also phytohemagglutinin (PHA = 5 μg/mL) and lipopolysaccharide (LPS = 10 μg/mL) activated splenocytes; then splenocytes proliferation assayed using the MTT ([3-(4, 5-dimethylthiazole-2-yl) -2, 5-diphenyl tetrazolium bromide]) method were done. On the culture supernatant interferon (IFN)-γ, interleukin (IL)-4, IL-10, and transforming growth factor (TGF)-β cytokines were measured. Clove ingredients (100 μg/mL and 1000 μg/mL) reduced PHA stimulated splenocytes proliferation and enhanced LPS stimulated cells expansion. Treated splenocytes showed suppression of IFN-γ release and induction of IL-4, IL-10, and TGF-β secretion (in the range of 0.1-1000 μg/mL). The results of this study suggest clove extracts could suppress the T cell cellular immunity and enhance humoral immune responses. In clove affection cytokine pattern shifted toward modulatory and Th2 responses and accelerator of humoral immunity cytokines.